This site may require a log-in in the near future. We are constantly being swamped by AI agents. If they continue to take down the site, we will be changing to requiring logins to access any item.

🍽️ aceclidine hydrochloride,(prescription)

AI Engines For more Details: Perplexity  Kagi Labs  You 

  1. Miotic Action: Aceclidine hydrochloride acts as a muscarinic receptor agonist, specifically targeting M1 and M2 receptors. By stimulating these receptors, aceclidine induces constriction of the pupil (miosis) and contraction of the ciliary muscle in the eye.

  2. Treatment of Glaucoma: Aceclidine hydrochloride is used in the treatment of glaucoma, a group of eye conditions characterized by increased intraocular pressure (IOP), which can lead to optic nerve damage and vision loss if left untreated. By constricting the pupil and facilitating aqueous humor outflow through the trabecular meshwork, aceclidine helps reduce IOP and prevent progression of glaucomatous optic neuropathy.

  3. Facilitation of Aqueous Outflow: In addition to its miotic effects, aceclidine hydrochloride may enhance aqueous humor outflow by stimulating the ciliary muscle to contract, thereby opening the trabecular meshwork and improving drainage of fluid from the anterior chamber of the eye. This mechanism of action contributes to the reduction of intraocular pressure in individuals with glaucoma.

  4. Adjunctive Therapy: Aceclidine hydrochloride may be used as adjunctive therapy in combination with other medications for the management of glaucoma, such as topical beta-blockers, prostaglandin analogs, or carbonic anhydrase inhibitors. Combination therapy allows for more comprehensive control of intraocular pressure and may be particularly beneficial in patients who do not achieve adequate IOP reduction with monotherapy.

  5. Dosage and Administration: Aceclidine hydrochloride is typically administered topically as eye drops. The dosage and frequency of administration may vary depending on the severity of glaucoma and the patient's individual response to treatment. It is usually instilled into the affected eye(s) one to three times daily, as directed by a healthcare professional.

  6. Ocular Side Effects: Common side effects associated with aceclidine hydrochloride eye drops may include ocular irritation, burning or stinging sensation, blurred vision, lacrimation (tearing), and conjunctival hyperemia (redness of the conjunctiva). These side effects are usually mild and transient, and patients are advised to report any persistent or bothersome symptoms to their healthcare provider.

  7. Systemic Effects: While aceclidine hydrochloride is primarily used topically in ophthalmic practice, systemic absorption can occur, especially if the medication is applied excessively or if the ocular surface is compromised (e.g., corneal abrasion). Systemic side effects may include bradycardia (slow heart rate), hypotension (low blood pressure), bronchoconstriction, and gastrointestinal disturbances.

  8. Contraindications: Aceclidine hydrochloride is contraindicated in individuals with known hypersensitivity to the drug or its components. It should be used with caution in patients with cardiovascular disease, respiratory disorders (e.g., asthma), urinary tract obstruction, or gastrointestinal conditions, as systemic absorption may exacerbate these conditions.

  9. Pregnancy and Lactation: The safety of aceclidine hydrochloride during pregnancy and lactation has not been established, and its use in pregnant or breastfeeding women should be avoided unless the potential benefits outweigh the risks. Healthcare providers should carefully weigh the risks and benefits of treatment in these populations and consider alternative therapies if possible.

;

Check for interactions on Supp.AI   |   📚 PubMed Citations

⚗️ Compensation for antibiotic usage

Data Contradictions — Limits of Certainity

Impacted of aceclidine hydrochloride,(prescription) On Probiotics

Rank Probiotic Impact
species Escherichia coli Reduces
species Lacticaseibacillus paracasei Reduces
species Parabacteroides distasonis Reduces

Bacteria Impacted by aceclidine hydrochloride,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

🧙?

📓 Direct Citations 👪👶 Indirect Citations Taxonomy Rank Effect
0 1 Escherichia genus Decreases
0 1 Parabacteroides genus Decreases
0 1 Bacteroides genus Decreases
0 1 Bilophila genus Decreases
0 1 Fusobacterium genus Decreases
0 1 Lacrimispora genus Decreases
0 1 Mediterraneibacter genus Decreases
0 1 Streptococcus genus Decreases
0 1 Lacticaseibacillus genus Decreases
0 1 Escherichia coli O25:H16 no rank Decreases
0 1 Escherichia coli O145:H34 no rank Decreases
0 1 Escherichia coli O16:H48 no rank Decreases
0 1 Escherichia coli O141:H4 no rank Decreases
0 1 Escherichia coli O139:H1 no rank Decreases
0 1 Escherichia coli O80:H26 no rank Decreases
0 1 Escherichia coli O158:H23 no rank Decreases
0 1 Escherichia coli O84:H7 no rank Decreases
0 1 Escherichia coli O2:K1:H4 no rank Decreases
0 1 Escherichia coli O2:K1:H7 no rank Decreases
0 1 Escherichia coli O78:H51 no rank Decreases
0 1 Escherichia coli O18ac:H14 no rank Decreases
0 1 Escherichia coli O85:H1 no rank Decreases
0 1 Escherichia coli O7:H15 no rank Decreases
0 1 Escherichia coli O68:H12 no rank Decreases
0 1 Escherichia coli O55:H7 no rank Decreases
0 1 Escherichia coli O1:K1:H7 no rank Decreases
0 1 Escherichia coli O15:H12 no rank Decreases
0 1 Escherichia coli O170:H18 no rank Decreases
0 1 Escherichia coli O155:H21 no rank Decreases
0 1 Escherichia coli O19:H7 no rank Decreases
0 1 Escherichia coli O2:K1:H5 no rank Decreases
0 1 Escherichia coli O20:H12 no rank Decreases
0 1 Escherichia coli O111 serogroup Decreases
0 1 Escherichia coli O121 serogroup Decreases
0 1 Escherichia coli O155 serogroup Decreases
0 1 Escherichia coli O177 serogroup Decreases
0 1 Escherichia coli O26 serogroup Decreases
0 1 Escherichia coli O3 serogroup Decreases
0 1 Escherichia coli O5 serogroup Decreases
0 1 Escherichia coli O86 serogroup Decreases
0 1 Escherichia coli O91 serogroup Decreases
0 1 Escherichia coli O103 serogroup Decreases
0 1 Escherichia coli O78 serogroup Decreases
0 1 Escherichia coli O43 serogroup Decreases
0 1 Escherichia coli O119 serogroup Decreases
0 1 Escherichia coli O157 serogroup Decreases
0 1 Escherichia coli O145 serogroup Decreases
0 1 Escherichia coli O1:HNT serotype Decreases
0 1 Escherichia coli O10:K5(L):H4 serotype Decreases
0 1 Escherichia coli O103:H11 serotype Decreases
0 1 Escherichia coli O103:H25 serotype Decreases
0 1 Escherichia coli O104:H21 serotype Decreases
0 1 Escherichia coli O111:H11 serotype Decreases
0 1 Escherichia coli O111:H8 serotype Decreases
0 1 Escherichia coli O112ac:H19 serotype Decreases
0 1 Escherichia coli O114:H49 serotype Decreases
0 1 Escherichia coli O118:H16 serotype Decreases
0 1 Escherichia coli O121:H7 serotype Decreases
0 1 Escherichia coli O123:H11 serotype Decreases
0 1 Escherichia coli O127:H27 serotype Decreases
0 1 Escherichia coli O127:H6 serotype Decreases
0 1 Escherichia coli O128:H2 serotype Decreases
0 1 Escherichia coli O128ac:H12 serotype Decreases
0 1 Escherichia coli O145:H25 serotype Decreases
0 1 Escherichia coli O145:NM serotype Decreases
0 1 Escherichia coli O146:H21 serotype Decreases
0 1 Escherichia coli O153:H2 serotype Decreases
0 1 Escherichia coli O156:H25 serotype Decreases
0 1 Escherichia coli O157:H43 serotype Decreases
0 1 Escherichia coli O157:NM serotype Decreases
0 1 Escherichia coli O165:H25 serotype Decreases
0 1 Escherichia coli O174:H2 serotype Decreases
0 1 Escherichia coli O174:H21 serotype Decreases
0 1 Escherichia coli O174:H8 serotype Decreases
0 1 Escherichia coli O176:H45 serotype Decreases
0 1 Escherichia coli O177:NM serotype Decreases
0 1 Escherichia coli O26:H1 serotype Decreases
0 1 Escherichia coli O28ac:NM serotype Decreases
0 1 Escherichia coli O29:H4 serotype Decreases
0 1 Escherichia coli O32:H37 serotype Decreases
0 1 Escherichia coli O6:H16:CFA/II serotype Decreases
0 1 Escherichia coli O69:H11 serotype Decreases
0 1 Escherichia coli O78:H12 serotype Decreases
0 1 Escherichia coli O79:H7 serotype Decreases
0 1 Escherichia coli O81:NM serotype Decreases
0 1 Escherichia coli O86:H34 serotype Decreases
0 1 Escherichia coli O91:H14 serotype Decreases
0 1 Escherichia coli O91:NM serotype Decreases
0 1 Escherichia coli ONT:H33 serotype Decreases
0 1 Escherichia coli O100:H21 serotype Decreases
0 1 Escherichia coli O121:H19 serotype Decreases
0 1 Escherichia coli O157:H7 serotype Decreases
0 1 Escherichia coli O16:H6 serotype Decreases
0 1 Escherichia coli O89m:H9 serotype Decreases
0 1 Escherichia coli O111:H- serotype Decreases
0 1 Escherichia coli O113:H21 serotype Decreases
0 1 Escherichia coli H20 serotype Decreases
0 1 Escherichia coli O150:H6 serotype Decreases
0 1 Escherichia coli O111:NM serotype Decreases
0 1 Escherichia coli O112ab:H8 serotype Decreases
0 1 Escherichia coli O99:H6 serotype Decreases
0 1 Escherichia coli O26:H11 serotype Decreases
0 1 Escherichia coli O145:H28 serotype Decreases
0 1 Escherichia coli O126:H45 serotype Decreases
0 1 Escherichia coli O2:H6 serotype Decreases
0 1 Escherichia coli O7:H4 serotype Decreases
0 1 Escherichia coli O1:H42 serotype Decreases
0 1 Escherichia coli O25:NM serotype Decreases
0 1 Escherichia coli O25:H1 serotype Decreases
0 1 Escherichia coli O7:K1 serotype Decreases
0 1 Escherichia coli O125ac:K+:H10 serotype Decreases
0 1 Escherichia coli O6:K2:H1 serotype Decreases
0 1 Escherichia coli O152:H23 serotype Decreases
0 1 Escherichia coli O15:H18 serotype Decreases
0 1 Escherichia coli O39:NM serotype Decreases
0 1 Escherichia coli O44:H18 serotype Decreases
0 1 Escherichia coli O2:K2:H1 serotype Decreases
0 1 Escherichia coli O8:H8 serotype Decreases
0 1 Escherichia coli O89m:H10 serotype Decreases
0 1 Escherichia coli O10:H32 serotype Decreases
0 1 Escherichia coli O6:H16 serotype Decreases
0 1 Escherichia coli O157:H- serotype Decreases
0 1 Escherichia coli O45:H2 serotype Decreases
0 1 Escherichia coli O103:H2 serotype Decreases
0 1 Escherichia coli O167:H26 serotype Decreases
0 1 Escherichia coli O104:H4 serotype Decreases
0 1 Escherichia coli O83:H1 serotype Decreases
0 1 Escherichia coli O9:H10 serotype Decreases
0 1 Escherichia coli O78:H4 serotype Decreases
0 1 Escherichia coli O139:H28 serotype Decreases
1 0 Escherichia coli species Decreases
1 0 Lacticaseibacillus paracasei species Decreases
1 0 Lacrimispora saccharolytica species Decreases
1 0 Bacteroides fragilis species Decreases
1 0 Parabacteroides distasonis species Decreases
1 0 Fusobacterium nucleatum species Decreases
1 0 Streptococcus salivarius species Decreases
1 0 Mediterraneibacter gnavus species Decreases
1 0 Bilophila wadsworthia species Decreases
0 1 Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases
0 1 Fusobacterium nucleatum subsp. nucleatum subspecies Decreases
0 1 Lacticaseibacillus paracasei subsp. tolerans subspecies Decreases

Impact of aceclidine hydrochloride,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0.3 0.3
Acne 0.3 0.3
ADHD 1 1
Age-Related Macular Degeneration and Glaucoma 0.4 -0.4
Allergic Rhinitis (Hay Fever) 1.7 0.9 0.89
Allergies 2.4 0.6 3
Allergy to milk products 0.9 1.3 -0.44
Alopecia (Hair Loss) 0.2 0.2
Alzheimer's disease 2.4 1.6 0.5
Amyotrophic lateral sclerosis (ALS) Motor Neuron 0.9 0.6 0.5
Ankylosing spondylitis 1.9 0.7 1.71
Anorexia Nervosa 0.7 0.9 -0.29
Antiphospholipid syndrome (APS) 0.9 0.3 2
Asthma 1.9 0.6 2.17
Atherosclerosis 1.5 0.3 4
Atrial fibrillation 1.3 1.6 -0.23
Autism 2.3 3.2 -0.39
Autoimmune Disease 0.9 0.9
Barrett esophagus cancer 0.3 0.3 0
benign prostatic hyperplasia 0.6 0.3 1
Biofilm 1.1 1.1
Bipolar Disorder 1.6 1.6
Brain Trauma 0.3 0.3 0
Breast Cancer 0.7 0.7
Cancer (General) 0.3 0.4 -0.33
Carcinoma 2.3 0.7 2.29
Celiac Disease 1.5 1 0.5
Cerebral Palsy 0.6 0.3 1
Chronic Fatigue Syndrome 1.6 0.8 1
Chronic Kidney Disease 1.4 0.3 3.67
Chronic Lyme 0.3 -0.3
Chronic Obstructive Pulmonary Disease (COPD) 1.3 0.6 1.17
Chronic Urticaria (Hives) 1.5 0.3 4
Coagulation / Micro clot triggering bacteria 1.9 0.3 5.33
Cognitive Function 1 0.3 2.33
Colorectal Cancer 3.3 0.9 2.67
Constipation 1.5 1.5
Coronary artery disease 1.6 0.6 1.67
COVID-19 2.5 0.8 2.13
Crohn's Disease 3.5 1.3 1.69
Cushing's Syndrome (hypercortisolism) 0.3 -0.3
cystic fibrosis 1.2 0.3 3
d-lactic acidosis (one form of brain fog) 0.6 0.6
deep vein thrombosis 1.6 0.6 1.67
Denture Wearers Oral Shifts 0.5 0.5
Depression 3.6 2 0.8
Dermatomyositis 0.3 0.3
Eczema 1.3 0.7 0.86
Endometriosis 2.2 0.6 2.67
Eosinophilic Esophagitis 0.3 0.3 0
Epilepsy 2.3 0.7 2.29
erectile dysfunction 1.3 1.3
Fibromyalgia 0.4 0.3 0.33
Functional constipation / chronic idiopathic constipation 2.5 1 1.5
gallstone disease (gsd) 2 0.3 5.67
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.7 0.3 1.33
Generalized anxiety disorder 2.2 0.6 2.67
Glioblastoma 0.3 -0.3
Gout 1.2 1.2
Graves' disease 0.7 0.6 0.17
Gulf War Syndrome 0.3 0.3 0
Halitosis 1 0.3 2.33
Hashimoto's thyroiditis 0.9 0.6 0.5
Heart Failure 2.4 2.4
hemorrhagic stroke 0.7 0.7
Hidradenitis Suppurativa 1.2 1.2
High Histamine/low DAO 0.6 0.6
hypercholesterolemia (High Cholesterol) 0.6 0.6
hyperglycemia 1.3 0.7 0.86
Hyperlipidemia (High Blood Fats) 0.3 0.3
hypersomnia 0.3 -0.3
hypertension (High Blood Pressure 1.6 1.2 0.33
Hypoxia 1.9 1.9
IgA nephropathy (IgAN) 1.3 0.1 12
Inflammatory Bowel Disease 3.1 2 0.55
Insomnia 0.7 0.6 0.17
Intelligence 0.9 0.9
Intracranial aneurysms 1 1
Irritable Bowel Syndrome 2.3 1 1.3
ischemic stroke 1.6 0.9 0.78
Liver Cirrhosis 3.2 1.8 0.78
Long COVID 2 1.3 0.54
Lung Cancer 0.9 0.9
Lymphoma 0.6 0.6
Mast Cell Issues / mastitis 1 1
ME/CFS with IBS 0.3 0.3 0
ME/CFS without IBS 0.4 0.5 -0.25
membranous nephropathy 0.3 0.3
Menopause 0.3 0.3
Metabolic Syndrome 3.3 1.9 0.74
Mood Disorders 3 2 0.5
multiple chemical sensitivity [MCS] 0.4 0.4
Multiple Sclerosis 2.1 1.5 0.4
myasthenia gravis 0.9 0.9
neuropathic pain 0.7 -0.7
Neuropathy (all types) 0.3 1 -2.33
neuropsychiatric disorders (PANDAS, PANS) 0.9 0.9
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 2.1 0.3 6
NonCeliac Gluten Sensitivity 0.3 0.3 0
Obesity 3.1 2.3 0.35
obsessive-compulsive disorder 2.5 0.7 2.57
Osteoarthritis 1.3 0.6 1.17
Osteoporosis 0.9 0.6 0.5
pancreatic cancer 1.3 0.6 1.17
Parkinson's Disease 2.9 2.2 0.32
Polycystic ovary syndrome 2.5 0.9 1.78
Premenstrual dysphoric disorder 0.4 -0.4
primary biliary cholangitis 0.3 0.6 -1
Primary sclerosing cholangitis 1.3 0.7 0.86
Psoriasis 1.2 0.9 0.33
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 2.1 0.9 1.33
Schizophrenia 2.2 0.7 2.14
scoliosis 0.6 0.3 1
Sjögren syndrome 1.3 0.7 0.86
Sleep Apnea 0.3 0.3 0
Slow gastric motility / Gastroparesis 0.9 0.9
Small Intestinal Bacterial Overgrowth (SIBO) 1.5 1.5
Stress / posttraumatic stress disorder 1.6 0.7 1.29
Systemic Lupus Erythematosus 2.6 0.3 7.67
Tic Disorder 0.3 0.3
Tourette syndrome 0.3 0.3 0
Type 1 Diabetes 1.9 0.6 2.17
Type 2 Diabetes 3.2 2.2 0.45
Ulcerative colitis 2.6 1.3 1
Unhealthy Ageing 1.7 0.4 3.25
Vitiligo 1.3 0.4 2.25

Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.

Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served.   Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA   Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.   Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.   Inventions /Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]